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Multidrug-resistant tuberculosis (MDR-TB, i.e. Mycobacterium 
tuberculosis resistant to both isoniazid and rifampicin with or 
without other drug resistance) is an increasing problem, especially in 
sub-Saharan Africa,1 where the significant increase in MDR-TB has 
been linked to the human immunodeficiency virus (HIV) epidemic.1
World Health Organization (WHO) guidelines recommend 
second-line injectable drugs (amikacin, kanamycin, capreomycin) 
for MDR-TB treatment.2 Patients are on long-term treatment plans 
including a second-line injectable drug for at least 6 months, or 
4 months after sputum culture conversion (i.e. 2 sputum cultures 
negative 1 month apart). These drugs have significant adverse effects, 
especially ototoxicity and nephrotoxicity. Unlike nephrotoxicity, 
ototoxicity is permanent.3 Risk factors include cumulative drug 
dose, duration of treatment, bacteraemia, renal or liver failure, and 
concomitant administration of drugs such as loop diuretics, that have 
a synergistic ototoxic effect.4
Some individuals may develop sudden profound sensorineural 
hearing loss following a single dose of aminoglycoside. This may 
be associated with a genetic susceptibility caused by the 1555A 
to G substitution on the mitochondrial 12S rRNA.5 Genetic 
predisposition may be predicted by identification of mutations in 
the MT-RNR1 gene.5,6 The literature suggests that mitochondrial 
mutations in the 12S rRNA are rare (0.09% - 3.96%), depending on 
the population studied.7,8 Owing to the rarity of these mutations, 
genetic predisposition may be unlikely to contribute significantly to 
the excessive risk of ototoxicity seen in developing countries. Other 
environmental factors may cause patients to be at increased risk. This 
study was divided into 2 parts of which the first relates to prevalence 
of the 6 known aminoglycoside-induced deafness mutations in the 
MT-RNR1 gene in a cohort of MDR-TB patients.5,6 Although these 
data have been published, they are cited where referred to in the 
text for completeness. The second part involves prospective hearing 
evaluation.
The high incidence of MDR-TB in South Africa and lack of 
efficacious alternative drugs mean that increasing numbers of people 
are at risk of developing aminoglycoside- or polypeptide-related 
ototoxicity. The lack of audiological monitoring results in ototoxicity 
going undetected. No data on the incidence of aminoglycoside-
induced deafness have been documented for South Africa.
The study aimed to: (i) document the incidence and audiological 
profile of aminoglycoside-induced hearing loss in HIV-positive and 
HIV-negative patients with MDR-TB; and (ii) formulate guidelines 
on the use of aminoglycosides in MDR-TB treatment relating to 
ototoxicity.
Methods
MDR-TB patients were recruited at Brooklyn Chest Hospital (BCH) 
in Cape Town, a dedicated 349-bed public sector TB hospital, that 
has received several wards for the management of MDR-TB patients.
On admission, all patients whose HIV status is unknown are 
routinely tested for HIV after informed consent and pre- and 
post-test counselling. Antiretroviral treatment is initiated when 
appropriate as part of comprehensive care.
Only patients with normal hearing on hospital admission and 
receiving aminoglycosides as part of their treatment within 3 months 
of hospitalisation were included. Serum aminoglycoside levels were 
not recorded. Patients underwent pure tone audiometry (PTA) and 
tympanometry on admission, then monthly for 3 months. Pure 
tone audiometry, including air and bone conduction threshold 
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measurements between 250 Hz and 8 000 Hz, was performed in a 
sound-treated room. Ototoxic threshold shift from the initial baseline 
audiogram was defined as: (1) >20 decibel (dB) decrease at any one 
test frequency, (2) >10 dB decrease at any 2 adjacent frequencies, or 
(3) loss of response at 3 consecutive frequencies where responses had 
previously been obtained. The severity of hearing loss was graded 
as: (1) mild: PTA 26 - 40 dB hearing level (HL), (2) moderate: PTA 
41 - 55 dB HL, (3) moderately severe: PTA 56 - 70 dB HL, (4) severe: 
PTA 71 - 90 dB HL, and (5) profound: PTA >90 dB HL. Age, gender, 
history of noise exposure, specific aminoglycoside therapy, presence 
of tinnitus, HIV status and whether patients were on combination 
antiretroviral therapy (cART) were recorded. Although pre-treatment 
baseline audiometry could not be performed on patients commenced 
on aminoglycosides by TB clinics prior to admission, only patients 
with normal hearing on admission were included. As part of the 
genetics arm of the study, peripheral blood samples were collected in 
EDTA-coated tubes from each study participant, and genetic testing 
was performed to screen for the 6 known aminoglycoside-induced 
deafness mutations in the MT-RNR1 gene (A1555G, C1494T, A827G, 
T1291C, T1095C and 961 indelC) using the new SNAPshot technique 
developed by the Tygerberg Genetics Department. Polymerase 
chain reaction (PCR) primers and SnapShot primers were specially 
designed that spanned the entire length of the MT-RNR1 gene. The 
SnapShot technique can detect the 6 known mutations in a single 
reaction.5,6
The t-test two-sample assuming unequal variances test was used 
to calculate the difference in the mean ages between HIV-positive 
and HIV-negative patients with hearing loss at a 95% confidence 
interval (CI). The odds ratio (OR) (95% CI) was used to calculate 
the measure of association of HIV and aminoglycoside-induced 
hearing loss. Fisher’s exact test was used to determine whether there 
were associations between gender and hearing loss, and to calculate 
whether there was a significant difference between HIV status and 
the severity of hearing loss.
The study was approved by the Committee for Human Research 
at Stellenbosch University (protocol number: N05/09/165) and the 
Research Ethics Committee at the University of Cape Town (ref: 
443/2005).
Results
We studied 153 patients; 2 refused HIV testing and were excluded. 
The median age was 36 years (range 14 - 70 years). All patients were 
on long-term treatment plans with second-line injectable agents; 
145 (96%) had received kanamycin, 5 (3%) streptomycin and 1 (1%) 
capreomycin.
Of 151 patients, 86 (57%) were HIV-positive. All HIV-positive 
patients were on cART, which comprised a combination of 2 
nucleoside reverse transcriptase inhibitors (NRTIs) and a non-
nucleoside reverse transcriptase inhibitor (NNRTI) or a protease 
inhibitor (PI).
Table 1 summarises hearing loss following 3 months of in-hospital 
aminoglycoside treatment; 87 (58%) subjects developed hearing loss 
that involved the higher frequencies (4 000 – 8 000 Hz) in all patients. 
In 5 (6%) patients with hearing loss, it progressed to involve lower 
frequencies (500, 1 000, 2 000 and 3 000 Hz); 13 (15%) developed 
asymmetrical hearing loss, and 11 (13%) complained of tinnitus.
Of patients who developed hearing loss, 74 (85%) had acquired 
MDR-TB and had received streptomycin in the preceding 6 months; 
13 (15%) had new MDR-TB (i.e. no previous anti-TB treatment or 
treatment for <1 month). Gender did not correlate with developing 
hearing loss (p=0.5; Table 1).
HIV-positive patients (60/86; 70%) were more likely to develop 
hearing loss than HIV-negative patients (27/65; 42%, OR 3.25, 95% CI 
1.65 - 6.37; p<0.001). Fig. 1 shows the age distribution. There was no 
significant difference between the ages of the two groups. The median 
age (standard deviation) of HIV-positive patients with sensorineural 
hearing loss was 34 (9.1) years, while HIV-negative patients had a 
median age of 40 (13.7) years. There was no association between HIV 
status and severity of hearing loss (Table 2). Patients who developed 
ototoxicity were mainly in the 30 - 39-year-old age group, which was 
representative of the study population’s age distribution.
None of 115 patients who consented to genetic testing had 
mitochondrial mutations. Of the 87 patients who developed hearing 
loss, 38 (44%) refused genetic testing, which makes assessment of the 
role of mutations in hearing loss equivocal.
Discussion
Aminoglycoside ototoxicity targets the sensory neuroepithelium of the 
cochlea.3 Loss of cochlear hair cells results in secondary degeneration 
of the auditory nerve.3 Outer hair cells are more susceptible than 
inner hair cells. Labyrinthine injury is usually gradual, progressive, 
symmetrically bilateral and permanent.3 However, as in our study, 
asymmetrical losses do occur.3 Ototoxic injury and associated hearing 
loss may progress for weeks following cessation of aminoglycoside 
treatment, owing to its long half-life in cochlear tissue.3 The basal 
region of the cochlea is more susceptible to injury than the apical 
region. This ‘cochleotopic’ gradient of susceptibility is expressed as 
high-frequency hearing loss, which extends to include progressively 
lower frequencies with more extensive cochlear damage.9 This is 
consistent with our finding that hearing loss, as documented by 
PTA, involved mainly higher frequencies (4 000 - 8 000 Hz). In 6% 
of patients, this progressed to involve lower frequencies (500, 1 000, 
2 000 and 3 000 Hz), consequently affecting speech comprehension.
Within 3 months of in-hospital aminoglycoside therapy, 57% of 
patients developed high-frequency hearing loss. Torun et al. reported 
ototoxicity in 42% of MDR-TB patients occurring at 4.7+1.7 months 
Table 1. Frequency of hearing loss after 3 months on aminogly-

















p=0.5 Fig. 1. Age distribution of HIV-positive and HIV-negative patients treated 
with aminoglycosides for multidrug-resistant TB who developed ototoxic 
hearing loss.
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of treatment.10 This frequent and early occurrence of ototoxicity may 
be due to extended exposure to aminoglycosides, as 40% of patients 
had previously been exposed to streptomycin.10 This result is similar 
to our study where 85% of patients had previously been exposed to 
streptomycin, and with findings that showed an association between 
ototoxicity and cumulative dose of aminoglycoside.4
No reported studies on aminoglycoside-induced ototoxicity 
in MDR-TB have included significant numbers of HIV-positive 
patients. Anti-TB treatment is frequently administered in HIV-
positive patients, including MDR-TB treatment. MDR-TB co-infected 
patients tend to have poorer outcomes and significant mortality in 
the first few months of MDR-TB treatment.1 Some studies, conducted 
in HIV-negative MDR-TB patients who were hospitalised and had 
adverse effects monitored for the duration of treatment, showed no 
compromise in cure when aminoglycosides were stopped and the 
treatment regimen changed when patients developed ototoxicity.9,10 
Consequently, in our setting, aminoglycosides are generally continued 
in HIV-positive patients co-infected with MDR-TB, despite the risk 
of developing hearing loss.
Evidence suggesting that cART may be ototoxic is mainly based 
on cross-sectional studies and case reports, and further studies are 
needed to establish these effects.11 In our study (the first to look 
at incidence of hearing loss in HIV-positive patients on cART and 
MDR-TB treatment), HIV-positive patients had a more than 3 times 
greater risk of developing ototoxic hearing loss.
Ototoxicity is diagnosed by comparing an initial audiogram – 
ideally obtained before initiation of ototoxic drugs – with hearing 
thresholds using serial audiograms, particularly ultra-high frequency 
thresholds.12 Patients receiving ototoxic antibiotics should be 
monitored weekly or biweekly.12 Oto-acoustic emissions (OAEs) are 
more sensitive at detecting auditory dysfunction than high-frequency 
pure-tone audiometry and have been used to monitor ototoxicity.12 
Owing to the long half-life of aminoglycosides in cochlear tissues, 
patients should be monitored for up to about 6 months following 
completion of MDR therapy.9 Although hearing loss was detected in 
57% of our patients, this figure could be greater if a more sensitive 
monitoring method such as high-frequency audiometry or OAE had 
been used, or if patients were followed up until after completion of 
aminoglycoside therapy. Once patients are discharged from Brooklyn 
Chest Hospital, they often cannot report back to the hospital for 
audiometric evaluation; consequently, because of the paucity of 
audiological services at peripheral clinics, monitoring for hearing loss 
following discharge from the hospital is non-existent.
Aminoglycoside treatment has commenced in the community 
owing to insufficient beds at TB hospitals, and hence the need 
to decentralise audiological services to TB clinics. The serious 
lack of audiological testing facilities, hearing aids and audiological 
rehabilitation in the Western Cape, is compromising MDR-TB care 
for patients who have become deaf as a consequence of ototoxic drug 
therapy.13
A study of patients’ awareness of ototoxicity with MDR-TB 
treatment reported that only 20% were aware that their treatment 
had ototoxic adverse effects, and that no patients on MDR-TB 
treatment were being monitored for ototoxicity.14 Even though 
more than half of the patients reported auditory symptoms since 
the commencement of treatment, none had been referred to an 
audiologist or otolaryngologist for management, despite almost half 
of them reporting that these symptoms affected their daily lives.14
When monitoring for ototoxicity, the aim is to detect hearing 
loss before it affects speech frequencies and the patient develops 
a communication problem. The treatment regimen can then be 
changed by either replacing the ototoxic drug or stopping it. 
MDR-TB is a life-threatening disease, and in most cases it may 
not be possible to safely alter the treatment without compromising 
cure of the patient. However, maintaining communication 
remains a major quality-of-life issue for patients. Therefore, the 
purpose of monitoring for ototoxicity is to assist the patient 
with communication strategies or amplification in the form of 
hearing aids when hearing loss occurs; it may also include tinnitus 
counselling. Managing MDR-TB patients with a holistic approach 
requires screening and monitoring for ototoxicity as part of the 
package of care of MDR-TB and possibly integration into national 
TB control programmes.
Conclusion
A high rate of hearing loss in patients on aminoglycoside-containing 
MDR-TB treatment was shown. The report is the first to show an 
association between HIV infection and ototoxicity in patients on 
MDR-TB treatment. Further studies are required to elucidate the 
mechanism of increased ototoxicity in HIV-positive patients. Hearing 
loss is likely to increase, given the high prevalence of HIV infection 
in South Africa, and information regarding possible hearing loss 
should be included as part of informed consent before commencing 
aminoglycoside therapy.
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